SCHEMBL1644482

SCHEMBL1644482

Cc1ccc([C@@H](C)NC(=O)c2ccc3cc(N4CCCC4)ccc3c2)cc1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 2/20 0.47
KMT2A Q03164 5/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
MEN1 O00255 2/20 0.46
MAPT P10636 2/20 0.46
POLB P06746 1/20 0.46
MCL1 Q07820 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TP53 P04637 1/20 0.45
GFER P55789 1/20 0.43
PHGDH O43175 1/20 0.43
HPGD P15428 1/20 0.42
SMYD3 Q9H7B4 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
ALDH1A1 P00352 2/20 0.41
HSP90AA1 P07900 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1643038 0.99 ACACB (0.46) ACACBKMT2ANPC1RAB9AMEN1
SCHEMBL1643824 0.98 ACACB (0.47) ACACBKMT2ANPC1RAB9AMEN1
SCHEMBL1645101 0.90 ALDH1A1 (0.51) ACACBKMT2ANPC1RAB9AMEN1
SCHEMBL1646174 0.85 GFER (0.42) KMT2ANPC1RAB9AMEN1MAPT
SCHEMBL1645472 0.84 GFER (0.41) KMT2ANPC1RAB9AMEN1MAPT
SCHEMBL1643774 0.81 TP53 (0.55) KMT2ANPC1RAB9AMEN1TP53
SCHEMBL1644966 0.79 KMT2A (0.51) KMT2ANPC1MEN1TP53ALDH1A1
SCHEMBL1644476 0.79 HPGD (0.52) KMT2AMEN1POLBSMN1; SMN2TP53
SCHEMBL1644493 0.78 ALOX5 (0.57) KMT2ANPC1RAB9AMEN1TP53
SCHEMBL1645249 0.78 UBE2N (0.46) KMT2AMEN1MAPTCYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088746-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME PFIZER INC. (US) 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088746-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME TRPV1, TRPA1, TRPV2 ACACB 1014/4885KMT2A 4280/4885NPC1 879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.